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Cancer remains one of the leading causes of death, albeit enormous efforts to cure the 
disease. To overcome the major challenges in cancer therapy, we need to have a better 
understanding of the tumor microenvironment (TME), as well as a more effective means to 
screen anti-cancer drug leads; both can be achieved using advanced technologies, including 
the emerging tumor-on-a-chip technology.   Here we review the recent development of the 
tumor-on-a-chip technology, which integrates microfluidics, microfabrication, tissue 
engineering and biomaterials research, and offers new opportunities for building and 
applying functional three-dimensional (3D) in vitro human tumor models for oncology 
research, immunotherapy studies, and drug screening.  In particular, tumor-on-a-chip 
microdevices allow well-controlled microscopic studies of the interaction among tumor cells, 
immune cells, and cells in the TME, of which simple tissue cultures and animal models are 
not amenable to do. The challenges in developing the next-generation tumor-on-a-chip 
technology are also discussed.  
 




Cancer remains one of the leading causes of death in the US and many other countries in the 
world, despite the extensive research and enormous efforts in drug discovery over the last 
few decades to cure the disease. This is partly due to the high cost of developing a new anti-
cancer drug, as well as the need to better understand cancer development and the tumor 
microenvironment (TME), including the roles of inflammation, different effectors and 
suppressors of immune responses, the heterogeneity of tumor stroma, and the function of 
tumor vasculature. To make significant improvements in cancer therapy, it is necessary to 
develop more effective approaches to screen anti-cancer drug leads and to have a better 
understanding of TME using advanced technologies, including the organs-on-chips 
technology [1-5]. 
To date most cancer research and anti-cancer drug screening have been conducted using cell 
culture and animal models.  While animal models of cancer can provide essential in vivo 
information of tumor growth and response to drug molecules, they could be very costly and 
the results may have very large variations among the animals used, thus difficult to get 
relevant statistics. Further, small animal models such as mouse models for cancer studies may 
not accurately represent what happens in human [6]. On the other hand, two-dimensional (2D) 
and three-dimensional (3D) cell cultures have been widely used for screening anti-cancer 
drugs, and studying cell signaling, proliferation, migration, and drug responses including 
altered protein/gene expression [7, 8]. These in vitro models may use co-culturing of multiple 
cell types in hydrogel matrices and include patient-derived cells [9, 10]. Although cell culture 
models are low cost, easy to handle, and typically have high repeatability, they may not be 
able to mimic microenvironment in an organ or an animal, thus are not suitable to study the 
effect of complex spatial organization and interaction of cells.  
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As an alternative to animal models and cell culture models to address the complex problem of 
cancer development and treatment, ‘tumor-on-a-chip’ technology has emerged recently as a 
new tool for cancer studies, providing a unique approach which integrates microfluidics, 
microfabrication, tissue engineering and biomaterials research, possessing the potential to 
significantly advance our understanding of cancer biology, allowing accelerated and cost-
effective drug discovery [4, 11]. As shown in Figure 1, a tumor-on-a-chip system consists of 
a microfluidic device that has tissue culture, nutrient and small molecule supply and waste 
removal functions (Figure 1A) [12]. Ideally, a 3D tumor could grow on the chip with a 
complex tissue structure comprised of tumor cells, stromal cells and blood vessels either self-
organized or spatially organized by design, mimicking some aspects of a tumor (Figure 1B) 
[13]. Examples of first-generation tumor-on-a-chip systems include a chip in which lung 
cancer spheroids were embedded in micropatterned 3D matrices immediately contiguous to a 
microchannel lined with endothelial cells (Figure 1C) [4], and a breast tumor-on-a-chip 
model comprised of the upper and lower cell culture chambers separated by an ECM-derived 
membrane that mimics a basement membrane in vivo (Figure 1D) [13]. Previous reviews in 
the literature on tumor-on-a-chip technology include the construction of 3D tumor models 
[14-17], its applications to specific cancer studies such as metastasis [18, 19], and its utilities 
in drug discovery [20, 21].  
This review aims to showcase the recent developments of the tumor-on-a-chip technology to 
mimic tumor microenvironments for cancer biology studies and biomedical applications. In 
Section 2, 3D in vitro tumor models established on microfluidic chips are reviewed. Specific 
microdevices mimicking various tumor microenvironments are elaborated in Section 3. In 
Section 4, examples of tumor-on-a-chip applications are discussed. The challenges in 
developing the next-generation tumor-on-a-chip technology are summarized in Section 5.  
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2. 3D in vitro tumor models on chip 
To characterize and study the invasiveness and detailed cancer biology of different tumors, in 
vitro culture of cancer cells from a tumor sample is routinely used. A 2D monolayer cell 
culture on thermoplastics is the gold standard for in vitro maintenance and multiplication of 
cells. Although 2D cell cultures have been widely used in various cellular assays (e.g., 
migration and toxicity assays) to characterize the metastatic property and drug response of 
cancer cells, 2D cultures cannot recapitulate the 3D architecture of tissue’s complexity, 
biophysical and biochemical property of extracellular matrix (ECM), and cell-cell 
interactions of human tumors [22-24]. Furthermore, cell cycle, cellular signaling, and drug 
sensitivity can be different if cell culture is performed in a 3D instead of a 2D 
microenvironment [25-27].  In vivo 3D models using animal xenografts are also popular but 
suffer from ethical concerns and unable to mimic human-specific biology and physiology. In 
vitro 3D tumor models are created by adapting several 3D tissue engineering methods to 
construct cells into three-dimensional space and mimic the in vivo tumor microenvironment 
in the body (Table 1). Among them, top down methods use decellularized scaffolds and 
bottom up methods utilize cells to build up tumor tissues for in vitro 3D tumor models. In 
tumor-on-a-chip systems, 3D tumor tissues are often cultured initially by established tissue 
culture protocol, then transferred onto the microfluidic chip for analysis. Thus, in vitro 3D 
tumor models can be adopted in tumor biology research and the development of therapeutics 
for personalized medicine [28, 29]. Next, we discuss common techniques for creating 3D in 
vitro tumor models in details (Figure 2). 
2.1 Ex vivo tumor culture 
Primary tumor tissues from biopsy or surgical resection can be embedded in ECM and 
cultured as an in vitro model [30-34] (Figure 2a). The embedded tumor sections retain the 
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tumor vasculature, nearby stroma, and the heterogeneity of the tumor cells. Microfluidic 
technology can be combined with ex vivo tumor section culture system for parallel drug 
sensitivity testing while maintaining continuous control over culture conditions [35]. 
2.2 Conventional transwell model 
Transwell inserts (also known as Boyden chambers) are widely used to perform conventional 
migration, invasion, and transendothelial migration assays, to assess the migration of cancer 
cells in combination with a chemical gradient. A transwell insert is composed of a polymeric 
porous membrane to allow cancer cells to migrate through the pores. A transwell insert is 
routinely used together with a multiwell plate with chemoattractants inside wells. In a 
migration assay, the ability for cancer cells to translocate through the pores is measured. The 
invasion assay further characterizes the migration of cancer cells through a 3D ECM layer on 
the porous membrane. In addition, the transendothelial migration ability of cancer cells can 
be characterized by using a transwell insert with a confluent endothelial cell layer grown on 
top of the membrane [36] (Figure 2b).  
The transwell assay is usually performed as an endpoint assay since it is difficult to image the 
kinetic behavior of cells migrating through the pores. Moreover, the steepness of 
chemoattractant gradient established between the well and inside the transwell insert is 
difficult to be controlled, making the transwell assay results semi-quantitative. However, 
transwell assays are quite suitable for more motile or invasive cell subpopulations as they can 
be recovered after the transwell assay [36].  
2.3 Tumor spheroids 
A tumor spheroid is derived from three dimensional aggregations of cells under non-adherent 
cell culture conditions [37]. The tumor spheroid resembles a small tumor mass in its 
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morphology, growth kinetics, nutrient transport, and cell-cell as well as cell-matrix 
interactions. Thus, the tumor spheroid serves as an excellent in vitro 3D tumor model [28, 38].   
Tumor spheroids can be generated by using single or multiple cell suspensions from 
permanent cell lines as well as dissociated cells from primary isolated tumor tissues and 
organotypic tissues [38]. Several common methods to generate tumor spheroids include 
suspension culture, hanging drop method, liquid overlay on non-adherent substrates, two 
phase encapsulation, and assembly by bio-conjugate chemistry or magnetic particles [28]. In 
the suspension culture, cells are placed in a spinner flask [39] (Figure 2c) or a NASA micro-
gravity vessel [40] (Figure 2d) to promote spheroid formation by inducing aggregation. The 
suspension culture is advantageous in high throughput production of spheroids, but the 
disadvantages are limited control over spheroid size and uniformity. The hanging drop 
method utilizes microtiter plate or microstructures to inversely hold a cell suspension droplet 
[41-47] (Figure 2e). The cells aggregate under gravity and subsequently form spheroids 
inside the droplet. The hanging drop method is of moderate throughput, but it possesses 
better control over the size of the spheroid. Microfluidic perfusion networks in combination 
with hanging drop methods have been utilized for continuous spheroid culture and drug 
screening [44-47]. Alternative to hanging droplet method, using the liquid overlay method, 
cell suspension is cultured on non-adherent substrates to produce spheroids [48-50] (Figure 
2f). The advantage of the liquid overlay method is its simplicity of operation, but the 
disadvantage lies in its poor control over spheroid size. Similarly, to produce tumor spheroids 
by avoiding cell adhesion to cultureware and inducing aggregation, an aqueous two phase 
system can also compartmentalize cell suspension and produce spheroids without the concern 
of drying and possible inefficiency in chemical transport and toxicity of an oil phase [51-53]. 
Three dimensional spheroids can also be formed by assembly of cells using bioorthogonal 
chemistry [54] or incubation of cells with magnetic particles [55, 56] (Figures 2g, 2h). 
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Recently, several microfluidic techniques have been developed to create tumor spheroids by 
either hydrodynamic trapping of cells in stagnation regions or in microwell structures [57-60], 
aggregating multiple cells in double-emulsions or hydrogel droplets [61-64], or aggregating 
cells on a digital microfluidic platform [65] (Figure 2i). The advantages of generating 
spheroids by microfluidics include control over spheroid size with continuous perfusion, as 
well as real time and in situ observation of spheroid formation kinetics. However, spheroids 
produced in some microfluidic models are difficult to be retrieved for off-chip analysis [57, 
63, 66]. 
2.4 3D cell culture in 3D matrices  
Tissue engineering methods have been adopted to create 3D tumor models. A scaffold is a 
biocompatible and chemically stable extracellular support structure serving as an instructive 
support for cell attachment, growth, and morphogenesis into tissues [67] (Figure 2j). A 
porous scaffold can be made from decellularized tissues or from fabrication of several natural 
ECM proteins or biocompatible polymers such as collagen, hyaluronic acid, silk protein, 
polyethylene glycol (PEG), and polylactic acid (PLA) [68, 69].  The scaffold is commonly 
prepared by freeze drying, electrospinning, phase separation, and microscale macromolecular 
self-assembly [70-74].  
Tumor cells cultured in scaffolds showed less sensitivity to chemotherapy and yield tumors 
with more invasive phenotypes [70, 75-77]. While the porous scaffolds have the mechanical 
and chemical characteristic of ECM for 3D tumor cell culture, the disadvantages include lack 
of vasculature structure in fabricated scaffolds that hindered perfusion for long term culture, 
as well as poor control on cell placement positions inside the scaffold. 
Alternative to scaffolds, a bottom-up approach using cells or few-cell spheroids as building 
blocks has emerged, inspired by the embryonic developmental processes [78, 79] (Figure 2k). 
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Hydrogels as extracellular matrix support are embedded with cells or few cell spheroids as 
building blocks (also known as bioinks) [80, 81]. Several natural polymers such as collagen, 
fibrin, Matrigel®, hyaluronan, chitosan, gelatin, and alginate, as well as synthetic polymers 
such as PEG can be used to create property-controlled hydrogel matrices.  The bioink 
containing multiple cell types and multiple ECMs can be printed at high density into large 
scale tissues and organs through the layer-by-layer additive bioprinting. The cell positions in 
three dimensions can be automatically and precisely controlled using bioprinting to create 
multicellular tissue with vasculature mimicking the in vivo tissue hierarchy and the 
microenvironment [80, 82, 83]. Common bioprinting methods include inkjet printing [84, 85], 
microextrusion printing [86, 87], laser-induced transfer printing [88], and stereolithography 
[89, 90].  
2.5 Microfluidic tumor-microvascular model 
The vasculature plays a pivotal role in tissue engineering and tumor biology [91]. Tissue 
engineering with vasculature is important for 3D persistent tissue culture. Moreover, the 
growth and dissemination of cancer requires growth of new vasculatures for nutrient 
transport [92]. Many cell types in the vasculature such as endothelial cells interact with 
cancer and modulate the tumor microenvironment as well as the cancer phenotype [93]. 
Conventional transwell assay, tumor spheroids, and scaffold approaches share the 
disadvantage of their inability to incorporate tumor-vasculature interactions in the culture. 
Using microfluidic technology, capillary lumen structures have been fabricated to mimic the 
microvasculature in tissues [94]. Common methods to create capillary lumen structures as 
microvasculatures include molding the capillaries in hydrogels by needles or rods [95-98], by 
photoresists [99-101], by sacrificial carbohydrates [102], or creating lumens based on viscous 
fingering instabilities [103, 104]. Alternatively, an endothelial vascular network as the 
microvasculature can be formed by endothelial sprouting in hydrogels [105-112], monolayer 
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on ECM hydrogel [113-115] or on a porous membrane [116, 117], and monolayer in 
microchannels [118, 119] (Figure 2l).  
Creating a functional microvasculature network together with 3D tumor model is essential to 
recapitulate the tumor microenvironment in vitro. By using a microfluidic perfusable 
platform to co-culture vasculature and cancer cells, it allows better kinetic examination of 
important cancer progression stages such as angiogenesis, intravasation, and extravasation in 
a controlled microenvironment [99, 110, 112, 120, 121]. Future challenges for microfluidic 
tumor-vasculature model include validation of the platform to clinical tumor tissues and 
increase complexity of the emulated microenvironment, such as chemical gradients and fluid 
flow at biological relevant speed and rhythms. Tumor microenvironments are complex and 
each component within often interact and affect one another. Current efforts have focused on 
mimicking specific tumor microenvironment to answer different biological questions. A 
microfluidic platform with active control components such as microvalves and micropumps 
can be programmed to recapitulate multiplex physical and chemical gradients together with 
multiple cell types to better mimic the complex microenvironment of a tumor. However, the 
design, experiment, and analysis on such platforms still pose great challenges that yet to be 
overcome. 
3. Mimicking tumor microenvironment using microdevices  
Cancer is a complex and heterogeneous metastatic disease modulated by genetic, epigenetic, 
and cellular signaling influenced by its surrounding stroma. The cancer cells grow 
uncontrollably into a primary tumor and interact with the supportive and immune cells as 
well as the biochemical and biophysical components of ECM in the nearby stroma.  Within 
the tumor microenvironment, three aspects are important: (1) hypoxia in the necrotic core of 
primary tumor tissue further drives metabolic shifts of cancer cells in the peri-necrotic niche; 
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(2) new vasculature growth is induced by the tumor and tumor-associated stroma for nutrients 
in the peri-vascular niche; (3) cancer cells interact with stroma to evade the immune system 
and adopt invasive and migratory phenotype to metastasize to distant tissues in the metastatic 
niche [93, 122] (Figure 3).  
In the peri-necrotic niche, the metabolic state of cancer cells is reprogrammed under hypoxia 
and ischemia due to an increase in the tumor mass. A necrotic microenvironment with 
dramatically low oxygen and nutrient concentrations as well as high acidity further induces 
the heterogeneity within cancer cell population and promotes cancer cells survival in the 
harsh environment, as well as their metabolic resistance to many cancer therapeutics [123, 
124]. 
Within the peri-vascular niche, by cross-talking with stroma, the cancer cells also induce 
outgrowth of new vasculatures (angiogenesis) and new lymphatic vessels 
(lymphangiogenesis) for nutrient and gas transport to enable cells survival and proliferation 
[125, 126]. However, the tumor vasculatures are often immature and leaky in comparison to 
the normal vasculature [127]. The peri-vascular niche also overlaps with the metastatic niche. 
New vasculature allows dissemination of cancer cells as they shed to circulating tumor cells, 
and among them tumor initiating cells can grow into secondary metastasis when seeded in 
distant tissues.  
The metastatic niche must be developed for invasive cancer cells to shed from the primary 
tumor, invade through the basement membrane into the stroma, intravasate into nearby 
vascular or lymphatic vessels, travel and survive in the circulatory system, extravasate into a 
distant tissue site, and form new micro-metastasis in new sites [128]. In some forms of cancer, 
cancer cells can also invade the nervous system during the process termed as peri-neural 
invasion, which is a contributor to tumor-related pain [129]. The complex sequential process 
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that cancer cells undergo is also known as a metastatic cascade [130]. Recently, the theory of 
tumor initiating cells or cancer stem cells as a rare group of circulating tumor cells suggest 
that the microenvironment is important for cancer stem cells to seed in distant tissues and 
form new metastasis [128]. 
Microfluidic platforms allow recapitulation, manipulation, and observation of cancer cell 
responses in tumor microenvironment on a chip. An in vitro model recapitulating the cancer 
cells as well as its microenvironment can enable more biomimetic and clinically relevant 
outcome to accelerate our knowledge in tumor biology and improve cancer therapeutic 
development. In this section, we briefly review the microdevices developed in the past few 
decades to study different tumor microenvironments, including peri-necrotic niche, peri-
vascular niche, and the metastatic niche [122, 131, 132]. 
3.1 Peri-necrotic niche: modeling hypoxia and necrosis 
In most tumor types, hypoxia is a mediator of tumor progression and therapeutic resistance 
[123]. As the primary tumor grows and its hyper-proliferating area increases, an imbalance 
between the hyper proliferative cancer cell growth and nutrient as well as the gas supply from 
the vasculature causes ischemia in the local tissue [123]. The new vasculature to deliver more 
nutrient and gas is induced by the perivascular niche and in part by the hypoxia. However, 
the new vasculature is often abnormal and fails to rectify the nutrient deficit. The persistent 
hypoxia in the tumor have several effects such as selection of survival cancer cell genotypes, 
up-regulation of pro-survival gene expressions, metabolic switches into anaerobic glycolysis, 
epithelial-mesenchymal transition (EMT), and therapeutic resistance [133]. Thus, creating an 
in vitro platform to recapitulate the hypoxia in an in vivo tumor microenvironment is very 
important. 
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In conventional tissue culture laboratory, precise control over gas condition is challenging 
due to continuous oxygen diffusion into the culture medium in ambient air [124]. A CO2 
incubator equipped with additional nitrogen gas mass flow controller can regulate the oxygen 
concentration within the incubator, but the oxygen gradient is still different in comparison to 
oxygen tension in the tissue. Alternatively, biochemical induction of key transcription factor 
of cellular hypoxia response such as hypoxia inducible factor (HIF) can be done to induce 
cellular signaling pathways in the hypoxia condition. The biochemical induction limits the 
spectrum of hypoxia study to dedicated signaling pathways [124].  
Alternatively, with microfluidics, the gas permeability of the chip material provides the 
advantage of creating a hypoxic microenvironment to simulate the peri-necrotic niche. 
Poly(dimethylsiloxane) (PDMS) is a biocompatible silicone rubber with high gas 
permeability and it has been a popular material for microfluidic chip fabrication by using soft 
lithography techniques [134, 135]. Low oxygen environment or an oxygen gradient can be 
created by flowing different gases, gas-equilibrated liquids, or oxygen scavengers in 
microfluidic networks [136-138]. Using poor gas-permeable thermoplastic as microfluidic 
chip material or embedding a thin thermoplastic sheet can also improve the control over the 
gas environment inside the chip [138-140].   
On 2D microfluidic platforms, Zhang et al. used SUM159 breast cancer cells to demonstrate 
increased migration in mesenchymal mode as well as production of lactate under hypoxic 
condition [141]. The acidic microenvironment derived from the metabolic reprogramming is 
also a factor for cell migration. Neutralization of the environmental acidity can inhibit the 
migration velocity of cancer cells and simultaneously improve the efficiencies of therapeutics 
targeting HIF-1 α, colony stimulating factor 1 receptor (CSF-1R), and C-C chemokine 
receptor type 4 (CCR4) [141]. These results demonstrate the importance of oxygen 
concentration as well as the pH level in the microenvironment to regulate the migration 
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potential of cancer cells. Other 2D microdevices can create stable oxygen gradients generated 
by oxygen scavengers, which become very useful to screen for cell survival and drug 
response under different oxygen concentrations [66, 138, 140, 142] (Figure 4A). 
The response of cancer cells to hypoxia environment in 3D can also be examined by cell 
embedded hydrogel models. Xu et al. demonstrated that the proliferation and invasion of 
glioblastoma U87MG cells under hypoxia conditions [143]. By flowing normoxia gas in one 
control channel and hypoxia gas in another near the PANC-1 pancreatic adenocarcinoma 
cells, Acosta et al. showed that hypoxia generated a more aggressive phenotype invading into 
the collagen gel [144] (Figure 4B).  
In addition, microfluidic platforms have been used to exam kinetic formation of necrotic core 
of a 3D cell embedded hydrogel tumor model [145, 146]. Ayuso et al. developed a 3D cell 
embedded hydrogel system to observe the kinetic formation of necrotic cores in HCT-116 
colon cancer cell model as well as U-251MG glioblastoma cell model over a 6-day period. 
Furthermore, real-time dynamic changes of oxygen and glucose concentrations, cell 
proliferation, apoptosis, reactive oxygen species formation, and drug response can all be 
studied in situ on chip [146] (Figure 4C). Co-culture multiple cell types with oxygen control 
is also possible with microfluidic platforms. Lin et al. demonstrated that both cell migration 
and VEGF165 and HIF-1α were upregulated in CaSki cervical cancer cells under hypoxia 
conditions [147] (Figure 4D). Similar response was also observed with U87 glioblastoma cell 
in an alginate hydrogel [148]. Expressions of VEGF provide evidence that cancer cells under 
hypoxic environment are stimulated to induce angiogenesis and that there can be cellular 
signaling cross-talk between peri-necrotic niche and peri-vascular niche. One imperative 
future direction is to develop more complex microdevices to recapitulate multiple 
microenvironments for detailed kinetic analysis of signaling crosstalks between various 
microenvironments, such as elucidation of the interdependency of necrosis and neo-
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angiogenesis in the crosstalk of peri-necrotic niche and peri-vascular niche. Within the peri-
necrotic niche, it has been challenging in validating the in vitro necrotic tumor model to 
tumor lysis and to incorporate stroma to investigate tumor-stromal cell interaction. Tumor 
lysis is the rapid death of large population of cells that causes sudden metabolic disturbances, 
leading to tumor lysis syndrome (TLS). TLS contributes to high mortality of cancer. It can 
happen spontaneously due to tumor necrosis or be initiated from anti-cancer therapies [149]. 
Although 3D tumor spheroids on chip developed recently exhibit necrotic cores as a micro-
tumor model [11], validation of this micro-tumor model with a human tumor and its tumor 
lysis kinetics remains a challenge. Moreover, incorporation of chemical gradients and co-
culturing stroma cells such as fibroblasts, macrophages, and natural killer cells to observe 
how necrosis contributes to stroma remodeling and chronic inflammation remains a difficult 
task [150]. Novel microdevice design integrated with biosensors and active flow control 
components such as microvalves is necessary to address these technical challenges. 
3.2 Peri-vascular niche: modeling angiogenesis and quiescence of cancer cells 
As a tumor grows and demands more nutrients for proliferation and survival, the tumor 
attracts neovascularization of blood vessels and lymphatic vessels through angiogenesis and 
lymphangiogenesis [125, 126]. It has also been suggested that endothelial cells in peri-
vascular niche can regulate quiescence of cancer cells as well as emergence after latency 
[151]. Using microfluidic technologies and tissue engineering, in vitro platforms with tumor 
and vasculature interactions can be developed and used to improve contemporary anti-
angiogenic therapy. Several hydrogel microdevices focused specifically on angiogenesis 
induction by cancer cells in the co-culture configuration. Chung et al. showed sprouting of 
endothelial cells into collagen hydrogel by VEGF gradient as well as by MTLn3 rat 
mammary adenocarcinoma cells [152] (Figure 5A). Cross et al. also demonstrated formation 
and lumen structure and invasion of hydrogel of human umbilical vein endothelial cells when 
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co-cultured with an oral squamous cell carcinoma cell line, OSCC3 [99]. Patra et al. showed 
that when co-culturing HUVEC cells with HepG2 hepatocellular carcinoma cells in tumor 
spheroids, HUVEC cells migrated outwards to proliferative edge and formed lumen-like 
structures under stimulation of pro-angiogenic factors [153]. Liu et al. used a 3D hydrogel 
microfluidic device to study angiogenesis induction by salivary gland adenoid cystic 
carcinoma and oral squamous cell carcinoma cells [154]. Both cell lines can induce strong 
angiogenesis and the angiogenesis can be inhibited under anti-angiogenic therapy. Aside 
from studying angiogenetic sprouting, Kim et al. demonstrated that a perfusable 
microvascular network could be created on chip as a vasculogenesis model [110] (Figure 5B). 
Instead of generating microvascular networks in a hydrogel, Bischel et al. and Nguyen et al. 
reported methods to pattern endothelia in a capillary lumen structure as a model of artificial 
blood vessel and angiogenesis assay [96, 104] (Figure 5C). 
In the peri-vascular niche, aside from signaling between cancer cells and endothelial cells, 
other cell-cell interactions and physiochemical factors in the stroma also influence the 
angiogenesis. Using a multi-culture microdevice, Theberge et al. demonstrated that the 
microenvironment would change when macrophages interacted with endothelial cells and 
fibroblasts [155]. In the presence of macrophage with fibroblast and endothelial cells, 
expressions of several pro-angiogenic factors such as HGF, VEGF, interleukin-8, and anti-
angiogenic factor matrix metalloproteinase-12 all increased. Angiogenesis are promoted but 
the endothelial tubules are abnormal due to the presence of other anti-angiogenic factors that 
are also secreted by macrophages. This observation supports our current knowledge that 
stroma cells in the microenvironment are also important in regulating the leaky vasculature 
cancer phenotype. These reported investigations demonstrate that microfluidic platforms 
offer new opportunities to recapitulate all the microenvironment components in vivo to yield 
physiologically and clinically results in an in vitro assay.  
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Aside from the biochemical factors and cell-cell interaction in the stroma that can affect 
angiogenesis, it has been found that the interstitial flow and the shear stress also regulate the 
sprouting of microvasculatures. The advantage of microfluidic models over other 
conventional 3D tumor models is their capability to create a perfusable vasculature with 
precise control with flow manipulations. Song and Munn showed that both interstitial flow 
and VEGF gradient regulate the angiogenic sprouting and vascular dilation on a tumor-
microvascular-on-chip [156]. Song et al. further demonstrated interstitial flow enhanced 
anastomosis, achieving perfusion by connecting multiple vascular sprouts [157].  
In addition, the shear stress acting on endothelial cells can also regulate barrier function and 
induce expression of pro-angiogenic factors, such as VEGF [158]. Buchanan reported 
increased secretion of pro-angiogenic factors when endothelial cells were co-cultured with 
MDA-MB-231 breast cancer cells [159, 160]. However, higher shear stress (10 dyne/cm2) 
applied on endothelial cells may increase perfusion and decrease secretion of several 
proangiogenic factors, as well as down regulate HIF-1α. These results indicate that the 
interstitial flow, biochemical factors, and cell-cell interactions all contribute to the regulation 
of angiogenesis in the tumor microenvironment. Using microfluidics, a perfusable and 
controllable platform supporting kinetic analysis of multiple cell co-culture is a promising 
approach to understand the pivotal roles of each factor and their interactions in regulating 
tumor angiogenesis. Testing the effectiveness and response to novel anti-angiogenic 
therapeutic tools using the tumor-on-a-chip platforms could provide detailed kinetic analysis 
and clinical relevant results.  
The key challenge of adopting peri-vascular niche is to incorporate multiplex chemical, 
physical, and gas gradients (oxygen and nitric oxide) to elucidate its interplay with the peri-
necrotic niche. The interdependency between necrosis and neo-angiogenesis is essential for 
understanding the growth of solid tumor and remodeling of the tumor microenvironment 
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[161]. To identify the essential features in recreating an in vitro perivascular niche, a high-
throughput microdevice is required to study microvasculature functions under different 
combinations of chemical and physical factors. The factors include but are not limited to pro-
angiogenic growth factors, stiffness of stroma, shear stress of interstitial flow, and 
concentration gradients of oxygen and nitric oxide.   
3.3 Metastatic niche: modeling tumor-stroma interaction and metastasis 
In a metastatic niche, cancer cells adapt into invasive and migratory phenotypes, shed from 
primary tumor, intravasate, extravasate, and colonize in distant microenvironment through 
the metastasis cascade. Many microfluidic devices have been developed to inspect each 
process in the metastatic cascade.  
First, the cancer cells must locally invade into nearby stroma. Chung et al. demonstrated the 
invasion of MtLn3, U87MG, and 10T 1/2 cancer cells into collagen hydrogels [152]. In 
microdevices, by taking advantage of the laminar flow and limited mass transport at 
microscale, stable chemical gradients can be established to investigate chemotactic invasion 
of 3D cancer model that is difficult to achieve by the conventional macroscale methods. Liu 
et al. studied how MCF breast cancer cells embedded in the basement membrane extract 
hydrogel are guided by epidermal growth factor (EGF) to invade the matrix [162]. Multiplex 
chemical gradients can also be easily established in a 3D microfluidic model. Kim et al. 
showed stromal cell derived factor-1α (SDF-1α) and EGF cooperatively modulated the 
migration of MDA-MB-231 cells [163].  
Microfabricated porous microdevices can also be used to select and examine migratory 
cancer cells from tumor spheroids guided by EGF gradients similar to that in a conventional 
transwell assay. Using such devices, Kuo et al. found decreased EpCAM expression in 
migratory cells, suggesting that the cells underwent the EMT and gained invasive properties 
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[164, 165]. 
The second stage for metastasis is for cancer cells to adhere to endothelium and intravasate 
into the circulatory system. Song et al. developed a microfluidic platform to culture uniform 
endothelium on a porous membrane to allow chemical transport and study how MDA-MB-
231 cells adhere to the endothelium through CXCL12-CXCR4 dependent signaling [116] 
(Figure 6A). Zervantonakis et al. created a microfluidic tumor-ECM hydrogel-vascular 
interface model to study how HT1080 fibrosarcoma cells interacted with the endothelial 
monolayer [166] (Figure 6B). While the fibrosarcoma cells have the ability to intravasate 
across the endothelium, when macrophages are present at the endothelium, macrophages can 
secrete TNF-α and increase endothelial permeability. As a result, the fibrosarcoma 
intravasation through the endothelium is increased. Such 3D microfluidic models combined 
with high resolution microscopy enable real time observation of cancer metastasis kinetics 
and further capture important parameters determining the microenvironment. Using a similar 
approach, Lee et al. demonstrated that TNF-α also promoted the intravasation of MDA-MB-
231 cells [167]. 
The intravasated cancer cells enter the blood vessel and become circulating tumor cells 
(CTCs) that travel throughout the body in the circulatory system. The CTCs have been a very 
active topic for the role in metastasis and the clinical potential as a diagnostic and prognostic 
tool [168]. While the amount of CTCs is very low in peripheral blood, it is hypothesized that 
cancer stem cells or tumor initiating cells can seed in distant tissues and grow into secondary 
tumors [169]. Many microfluidic platforms have been developed for capture and analysis of 
CTCs, more dedicated articles can be found in the literature [170-172]. 
At distant sites, the circulating tumor cells need to extravasate through the endothelium and 
settle in the new microenvironment. Zhang et al. demonstrated that chemokine CXCL12 
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could stimulate salivary gland adenoid cystic carcinoma cells to extravasate through HUVEC 
endothelium [119]. The stimulated extravasation can also be inhibited by CXCR4 antagonist 
AMD3100. Chen et al. employed a microvascular network in hydrogel and loaded MDA-
MB-231, HT-1080, and MCF-10A cells by perfusion [109] (Figure 6C). The extravasation 
events (transendothelial migration) of the cells from the microvascular network into hydrogel 
can be tracked via time-lapsed microscopy. Interestingly, different cancer cell subpopulations 
exhibit different migration capabilities. Trapped cells as well as clustered cells showed much 
higher rate of migration into the ECM. Activation of tumor integrins β1 was found to be 
necessary for both extravasation and bone marrow colonization using the microvascular 
network microdevice [173]. Several microfluidic models also employed the ECM hydrogel-
endothelium monolayer interface models commonly used in intravasation to study cancer 
extravasation by seeding cells in different microfluidic channels [112, 174, 175].  
In the metastatic niche, other stromal cells and biophysical components also influence cancer 
cells’ invasiveness. Multiple cell co-culture microdevices have been developed to study the 
effect of cell-cell interactions such as autocrine and paracrine signaling on the invasiveness of 
the cancer cells. Small vesicles containing nucleic acids and proteins (termed exosomes) may 
be the carriers to carry signaling molecules between the cancer and stromal cells [176]. Hsu 
et al. developed a 2D three-chamber PDMS microfluidic chip with microvalve control to 
selectively flow the conditioned medium of fibroblast, macrophages, and CL1-0 lung cancer 
cells to investigate how paracrine signaling from tumor stroma affected cancer cell 
invasiveness [177] (Figure 6D). Lung cancer cells release TGF-β1 to transform fibroblasts 
into myofibroblasts and in return promote the migration speed of cancer cells. However, 
macrophages can immunomodulate the myofibroblasts and the cancer cell migration speed 
decreases in the macrophage-pretreated and myofibroblast conditioned media. Interestingly, 
instead of pretreatment, direct combination of macrophage conditioned medium and 
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myofibroblast conditioned medium resulted nearly three-fold increase of lung cancer cells’ 
migration speed [177]. Similar to other tri-culture microfluidic models, these results imply 
that the responses of cancer cells influenced under multiple factors can be quite complex and 
diverse [155, 177].  
Multiplex 3D co-culture microdevices also serve as useful tools to investigate how the stroma 
interacts and modulates cancer cells. A breast cancer-on-a-chip device developed by Choi et 
al. recapitulate the mammary duct and stroma as well as tumor spheroid in one microdevice 
model [13].   Jeong et al. used multiple hydrogel chambers embedded with tumor spheroids 
and fibroblasts to show that cancer associated fibroblasts promote cancer cell proliferation 
and drug resistance [178]. Liu et al. developed a four-chamber co-culture microdevice to 
simulate the microenvironment of bladder cancer with T24 cancer cells, macrophages, 
fibroblasts and HUVECs embedded in hydrogel [179]. The bladder cancer cells grew into 
reticular structure and stromal cell phenotype changed despite the lack of 3D tissue hierarchy 
in the system. Bischel et al. patterned a 3D lumen structure in a microdevice by viscous 
fingering method and successfully verified that the invasion of ductal carcinoma in situ 
(DCIS) of breast cancer cells was induced by mammary fibroblasts [180] (Figure 6E). By 
using second harmonic imaging, increased collagen modifications were found near the 
invasive region, suggesting that the extracellular matrix was remodeled by invasive cancer 
cells.  
Aside from cell-cell interaction in the metastatic niche, physical factors such as interstitial 
flow and mechanical stimulation can regulate invasiveness of cancer cells. Polacheck et al. 
developed a microfluidic culture chip to apply a stable interstitial flow to MDA-MB-231 cells 
embedded in a collagen hydrogel [181]. Cancer cells at different densities responded to 
interstitial flows differently. At low cell density, cells migrated with the interstitial flow, and 
the migration was dependent on CCR7 signaling. When CCR7 signaling was blocked, the 
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migration directionality was reversed.  Jeon et al. demonstrated that the presence of 
interstitial flow in a microvascular network reduced the extravasation of cancer cells and 
decreased the permeability of vasculature [112]. By applying cyclic tensile strain on 
myofibroblasts in a PDMS microdevice, Huang et al. showed that tensile strain reduced the 
ability of the myofibroblast to accelerate cancer cell migration [182]. The effect of cyclic 
tensile strain is also modulated by IL-1β that are secreted by other cells in the stroma, which 
implies the complicated interaction between cancer cells and different stromal cell types in 
the microenvironment.  Stiffness of ECM and stromal cells can also regulate the invasiveness 
of cancer cells [183, 184]. Finally, transepithelial potential differences in tissues can generate 
physiological electric field and guide the migration of cancer cells through electrotaxis [185-
187]. In short, many metastatic niche studies verified that invasive cancer cells could interact 
and modulate with biophysical and biochemical properties of the stroma, as well as with all 
the cellular components in the complex microenvironment. Similar to the challenges in 
mimicking tumor microenvironments, incorporating multiplex chemical, physical, and cell 
factors in a metastatic niche is critical in order to create a reliable in vitro micro-tumor model 
and investigate how each component contributes to the modulation of the metastatic cascade. 
4. Applications of tumor-on-a-chip technology 
The development and application of tumor-on-a-chip technology has the potential to address 
many important biological questions by replicating major aspects of the tumor structure, 
microenvironment and tumor biology. For example, a tumor-on-a-chip system may allow us 
to study the complexity of cancer growth and progression in a controlled fashion, capture and 
analyze spatiotemporal dynamics of tumor cells interacting with stromal cells, immune cells 
and other cells in the blood, and perform high-resolution imaging to understand some of the 
molecular and cellular mechanisms of tumor growth and metastasis. Tumor-on-a-chip 
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approaches may allow the use of patients’ own tumor cells to determine how they respond to 
anti-cancer drug or immunotherapy and to better predict cancer aggressiveness, achieving the 
best possible clinical outcome by extending survival and reducing the chances of relapses and 
emergence of drug-resistant tumors. Although the technology is still in its early stages, the 
current designs of microfluidic tumor-on-a-chip systems have already shown promises in 
growing simple 3D tumors and having good controls over the tumor microenvironment. 
Some of the applications include multiplexed drug screening, transport of nanoparticles, 
transcription analysis, proteomic analysis, and metabolic changes in cells. 
4.1  Multiplexed drug screening 
Conventional pre-clinical drug screening is expensive and time-consuming, and requires 
large number of cells. Recent advances in microfluidics technology have enabled cost-
effective high-throughput screening. Aside from having a lower cost and faster processing 
speed, microfluidics chips require a much smaller sample volume. Furthermore, these chips 
can be customized to monitor the effects of anticancer drugs on any number of parameters, 
including cell migration [188]. Specifically, Zhang et al. developed a microfluidic device 
with 3120 different microchambers in which cell density was varied throughout the chambers, 
and the average migration velocity and the percentage of migrating cells were quantified. 
This device can create chemical gradients of multiple anti-tumor drugs and generate 
multiplicates of sample data on a single chip to specifically monitor the mesenchymal 
migration and survival of tumor cells upon exposure to drugs that inhibit cell migration, 
including axitinib [189]. In a study by Sobrino et al, vascularized microtumors were created 
on a PDMS membrane to study the effects of vascular targeting agents, such as Apatinib and 
Linifanib [132] (Figure 7A). A key drawback to this approach is the absorption of the agents 
in question by the PDMS membrane. Further work is needed to determine the effects of the 
partition coefficients of various types of drugs in different types of microfluidic platforms. 
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Choi et al. explored the tumor microenvironment as a crucial regulator of tumor progression 
by designing a microchip with two microchannels surrounding a basement membrane with 
epithelial and stromal cells to simulate pre-invasive breast cancer lesions. Tumor spheroids 
were cultured on top on the epithelial cell layer [13] (Figure 7B). This model replicates the 
3D microarchitecture in vivo and enables simulation of physiological delivery of 
intravenously administered paclitaxel by continuous flow through the lower microchannel 
[13]. This device can be scaled up easily for multiplexed screening of drug molecules based 
on their efficacy and safety, and the platform is flexible enough to be used for models of 
other types of cancer.  
4.2 Transport and delivery of nanoparticles 
Microfluidic systems can be used to evaluate nanoparticle transport in vitro and optimize 
nanoparticle designs by selecting the right size, shape and surface chemistry, such that the 
nanoparticle systems identified would have higher rates of success in drug delivery or in vivo 
imaging, thereby reducing the number of costly animal studies [190]. Recently, Albanese et 
al. designed a tumor-on-a-chip microfluidic model to study how nanoparticles were 
transported in the 3D tumor spheroid. They showed that flow rate affected the accumulation 
of the nanoparticles in the in vitro spheroid model [11]. Kwak et al. developed a tumor-
microenvironment-on-chip (T-MOC) model to recapitulate the complex transport of drugs 
and nanoparticles within a 3D model of breast cancer and endothelial cells [191].  They could 
quantify the effects of nanoparticle size on the extravasation and interstitial diffusion. There 
was a significant decrease in both parameters between the 100 nm and 200 nm nanoparticles 
[191]. Bagley et al. demonstrated the use of plasmonic nanoantennae to enhance transport 
into a model of ovarian cancer via heat generation. They also used temperature-controlled 
microfluidic devices to measure diffusion of the nanoparticles in vitro [192]. The use of 
microfluidic devices to aid in the rapid development of translatable nanoparticles for tumor 
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microenvironment studies is a very active and promising area of research.  
4.3  Analysis of transcription  
Using droplets in a microfluidic platform is an effective way to conduct transcription analysis 
on the level of single cells. Zhang et al. developed a microfluidic device for performing 
single copy RT-PCR (Reverse Transcription Polymerase Chain Reaction) using agarose 
droplets, which contained both sample and RT-PCR reagents [193]. The platform was 
validated by showing significant differences in expression of the EpCAM cancer biomarker 
gene between different types of cancer cells [193]. Microfluidic droplets were also used in a 
separate study by Hayes et al. to evaluate extracellular matrix gene expression levels in 
patient samples of colorectal cancer in order to find a potential correlation between 
differential expression and metastatic potential [194]. A study by Jang et al demonstrated that 
a droplet-based model of microtumors can be used effectively to analyze the gene expression 
of markers related to the EMT [195]. Developing high-throughput single cell analytical 
techniques and using patient samples to find correlates or clusters of genes of interest has the 
potential to greatly expand the number of therapeutic targets currently known to us.  
4.4  Proteomic analysis 
Quantitative analysis of the cancer proteome has the potential to have a tremendous impact 
on not only molecular diagnostic technology, but also on discovering novel therapeutic 
targets. In a study by Sun et al., a microfluidic cytometry imaging system was developed that 
is capable of quantitative, single-cell proteomic analysis in both cultured cell lines and patient 
samples, using as little as 1,000 cells. Its clinical application was demonstrated by analyzing 
four proteins within the mTOR signaling pathway using human brain tumor samples, and 
comparing the results to that using well-established clinical immunohistochemical (IHC) 
protocols. The IHC findings corroborated the single-cell analysis in all but one case [196]. In 
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a study by Jeong et al, human colorectal cancer cells were co-cultured with fibroblasts on a 
PDMS microfluidic chip, which was then used to quantify the level of proteins involved in 
angiogenesis, apoptosis, and cell motility [178] (Figure 7C). On a larger scale, Xu et al 
designed a biomimetic multi-organ microfluidic chip to assess changes in the expression 
levels of CXCR4, RANKL, and other markers in the various ‘distant organs’ after tumor cell 
invasion [197]. 
4.5  Analysis of metabolites and energy metabolism 
Cancer cells tend to continuously multiply without cell cycle check, thus understanding the 
mechanism of cancer cell energy metabolism is critical to both basic cancer research and 
cancer therapeutics. Microdevices are well suited to study tumor cell energy metabolism by 
controlling both the oxygen supply and nutrient depletion to the cells. Xu et al. designed a 3D 
microfluidic chip to study the energy metabolism in tumor-associated fibroblasts and bladder 
tumor cells, specifically measuring lactic acid concentration and mitochondrial-related gene 
expressions [198]. Culture media were perfused through the microfluidic channels which 
contained fibroblasts or bladder tumor cells or both. The conditioned media of co-cultured 
cells had the highest lactate concentration, suggesting that the aerobic glycolysis increased 
under the co-culturing condition. This microfluidic platform provided a unique non-contact 
co-culture condition to investigate energy metabolisms between different cell types. Zhu et al. 
also examined cancer cell metabolism using a microfluidic tumor-endothelial cell co-culture 
system. Lactic acid and mitochondrial protein levels were measured and found to increase in 
the co-culture group [199]. Similar approaches can also be adopted to screen for drug 
resistance, or investigate energy metabolism in regenerative medicine [200, 201]. 
Since cancer cells that release high levels of lactate correlate to increased metastasis [202], 
microdevice has been developed to perform single cell analysis of metabolites. Mongersun et 
  27
al. developed a droplet microfluidic platform that quantifies the lactate release rate down to 
single-cell resolution. The PDMS/glass microfluidic chip with the flow focusing design 
produced droplets containing single cancer cells and allowed real time monitoring of lactate 
release within each individual droplet [203]. Performing metabolic analysis on single 
populations of tumor cells can yield significant insight into the mechanisms of tumor 
heterogeneity and energy metabolism reprogramming, both are important for predicting 
cancer metastatic potential as well as drug resistance [204]. 
5. Conclusions and future perspectives  
To fully realize the potential of tumor-on-a-chip approaches, a number of key questions must 
be addressed. For example, how to model the mechanism of intravasation and extravasation 
using such a system; how to allow tumor-associated tissues mature in a chip with respect to 
self-organization, if there is a minimum number of components needed to construct a tumor-
on-a-chip system that allows a tumor to grow on a chip. Clearly, different approaches need to 
be developed to quantitatively analyze tumor-matrix interactions (including, e.g. matrix 
remodeling and growth factors) in order to understand the enhanced permeability and 
retention (EPR) effect as well as the phenotype of dormancy. It is also very important to 
reflect the heterogeneity and evolution present in the tumor by using a tumor-on-a-chip 
system. As a control, we need to have both cancerous and normal tissues grown on a chip in 
order to compare different features. It is also possible to use tumor-on-a-chip approaches to 
study tumor-immune response as how bacteria and virus trigger oncogenesis.  
Tumor-on-a-chip systems may have different designs and complexities, depending on the 
medical relevance and biological question(s) to be addressed. It is necessary to avoid 
constructing oversimplified or overcomplicated systems, and have sufficient complexity 
driven by need.  Accordingly, a tumor-on-a-chip system may include one or more of the 
following considerations: (a) structural features including 3D tumor constructs and 
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microfluidics designs; (b) biomechanical and kinematic parameters such as matrix stiffness 
and anisotropy, cell adhesion, and flow conditions; (c) cell types and sources, including 
patient cells, cell lines, stromal cells, stem cells and progenitor cells; (d) cell metabolism, 
culture media transport, waste removal and cytotoxicity; (e) physiological levels of 
concentration and concentration gradients of circulating factors. To accurately capture 
important features of a tumor, it may also be necessary to consider metastatic sites, 
recapitulation of cancer-immune cells interactions, and integrate real-time, on-chip 
monitoring of relevant biophysical and biochemical parameters. While preformed scaffolds 
for tumor structure and organization have certain advantages, the self-organized tumor 
structure through evolution of cell-cell interaction may provide a better model for tumor-on-
a-chip platform. It is likely that different tumor-on-a-chip systems with different features and 
complexities are needed for different cancers and/or address different questions. 
 The emerging tumor-on-a-chip technology has the potential to transform the fields of 
oncology and cancer biology.  However, there are roadblocks in technology development, 
including design, optimization, analysis, and validation. Consistency of device properties 
(such as its biocompatibility, fit for purpose, ease of handling, and mechanical properties) 
relies on material choices.  Most devices have been built on PDMS-based substrates, which 
have been outstanding for studies on biological mechanisms, but have severe limitations 
when used with hydrophobic drugs. Other moldable and printable surrogates must be 
explored to overcome this limitation such as off-stoichiometry thiol-enes [205], epoxy resin 
[206], and perfluorinated polymers [207].  Systematic manipulation and automation of the 
physical and chemical parameters within the microfluidic device will require integration of 
micro-device printing experts with polymer chemists and material scientists.  Material choice 
and user operability are chief concerns when considering the scalability of the device and 
GMP (good manufacturing practice) development. Further, it is important to establish the 
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shelf-life (longevity post-manufacturing and pre-utility) and sustainability (e.g., duration of 
cell culture and waste removal in the system) of tumor-on-a-chip devices.   
Although the potential of tumor-on-a-chip systems as cancer research tools has been 
demonstrated through proof-of-concept reports, major challenges for translating the 
technology to clinical practice remain, including the validation of device functionalities by 
comparing with well-established in vivo tumor models, and the correlation of the results 
obtained using tumor-on-a-chip systems with clinical tumor tissues. Tumor-on-a-chip system 
has the unique advantages of precisely manipulating the physical and chemical factors in the 
tumor microenvironment, co-culturing stromal cells with cancer cells, providing optical 
window for real time observation of molecular and sub-cellular processes through 
microscopy, and integrating with biosensors for quantitation [208]. Tumor-on-a-chip system 
can be superior over animal xenograft models concerning physiochemical differences, 
biological variation, cost, and ease of statistical analysis. To fully realize the potential of the 
tumor-on-a-chip technology, it is essential for researchers in biomedical engineering, material 
science, biophysics, cell biology, and oncology to make concerted efforts in designing and 
optimizing tumor-on-a-chip systems for cancer research, drug discovery, and in translating 
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Table 1. Comparison of in vitro tumor models 
3D tumor models Processes Advantages Disadvantages 




Recovery of motile cell 
population, easy to 
perform 
No control over gradient, 
endpoint assay, inability to 
create multiplex gradient, 
no cell-cell interaction 
Tumor spheroids Mimicry of tumor 
mass in 3D 
A micro tumor with 3D 
structure, necrotic core, 
and nutrient transport 
property; perfusable with 
microfluidics   
No vasculature on 
spheroids 
Ex vivo tumor section Direct in situ analysis 
on in vitro cultured 
tissue 
Retains primary tumor 
and stroma 
Require primary tumor 
tissue for every experiment 
Scaffold Solid extracellular 
support for 3D cell 
culture 
A characterized ECM 
structure for 3D cell 
culture 
Difficult to uniformly 
distribute cells in scaffolds. 
Difficult to perfuse the 
model 
Bio-ink 3D printing Layer-by-layer 
construction of cells 
Printing multiple cell 
types and ECMs; high 
spatial precision 
Specific bioink formulation 









for kinetics, incorporation 
of gradients 






Figure 1.  The concept of tumor-on-a-chip. (A) A microfluidic device that has tissue 
culture, nutrient and small molecule supply and waste removal functions for growing tumors 
on a chip.  Adapted from [12].  (B) The ultimate goal is to grow 3D tumor on chip with a 
complex tissue structure consisting of tumor cells, stromal cells and blood vessels.  (C) An 
example of tumor-on-a-chip in which lung cancer spheroids were embedded in micro-
patterned 3D matrices immediately contiguous to a microchannel lined with endothelial cells. 
Reprinted with permission from Macmillan Publishers Ltd. (D) The physiological 
microarchitecture is recapitulated in the breast-cancer-on-chip microdevice with two cell-
culture chambers separated by an ECM-derived membrane. Adapted from [13] with 
permission from the Royal Society of Chemistry. 
Figure 2. Existing techniques to create 3D in vitro tumor models. (a) An ex vivo tumor 
culture based on a tumor tissue section. (b) Single tumor cells embedded in hydrogel on 
transwell insert is one of the earliest 3D model that can also characterize the invasiveness. 
Tumor spheroids can be prepared from dissociated cells from tumor or circulating tumor cells 
(CTCs) by (c) spinning mask method, (d) NASA microgravity apparatus, (e) hanging drop 
method, (f) liquid overlay method, (g) magnetic levitation after cells are incubated with 
magnetic nanoparticles, (h) bio-orthogonal chemistry, and (i) microfluidic methods such as 
flow focusing, droplet microfluidics, and digital microfluidics. Alternative to spheroids, 3D 
tumor models can be fabricated by seeding cells in artificial 3D matrices. (j) Cancer cells can 
be seeded in fabricated scaffolds. (k) Cell-embedded bio-ink can be printed as building 
blocks for tissues. (l) Microfluidics-microvascular model uses a microdevice to model a 
multiple tissue type microenvironment. Modified from [28, 29]. 
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Figure 3. A tumor microenvironment of solid tumor consists of peri-vascular niche, 
metastatic niche, and peri-necrotic niche. Hypoxia is a result of growth/nutrient imbalance 
induce metabolic reprogramming in the peri-necrotic niche. Tumor induces angiogenesis and 
lymphangiogenesis in effort to gain more nutrient and access to circulatory system in peri-
vascular niche. Cancer cells shed, invade, intravasate, extravasate to metastasize to distant 
tissue and create secondary tumors. The tumor microenvironment is complex and composed 
of cell-cell interaction and biophysical as well as biochemical interactions between the tumor 
and the stroma. Modified from [128, 132]. 
Figure 4. Microdevices to model the peri-necrotic niche. (A) (i) The cross-sectional view 
of oxygen gradient generating microfluidic chip by Chen et al. (ii) A549 cell culture for 6 
hours with and without oxygen gradient (hyperoxia). Hyperoxia induced cell death is visible 
on the right side of the channel. (iii) A549 cell culture under 4 hours 1mM hypoxia dependent 
anti-cancer drug Tirapazamine (TPZ) with and without oxygen gradient. Increased efficacy 
of TPZ is seen on the left side. Adapted from [66] with permission of The Royal Society of 
Chemistry. (B) (i) A microfluidic chip by Acosta et al. to create oxygen gradient by diffusion 
of gas between two gas supply channels. (ii) The predicted oxygen concentration gradient at 
steady state within the cross-section of microfluidic device. (iii) Increase invasion into 
collagen hydrogel by PANC-1 cancer cells under hypoxia condition. Reprinted from [144], 
with permission of AIP Publishing. (C) (i) A microdevice by Ayuso et al. to provide nutrient 
and oxygen gradient across it. (ii) Increased hypoxia in HCT-116 colon cancer cells imaged 
by hypoxia-sensitive dye. [146]. (D) (i) Schematic diagram of an integrated microfluidic 
oxygen gradient generator by Lin et al. (ii) cell migration of CaSki cancer cells and HUVEC 
endothelial cells under 5% O2 concentration for 2 days. Adapted from [147].  
Figure 5. Microdevices to model the peri-vascular niche. (A) (i) Schematic for a 3D 
microfluidic chip with scaffold channel for hydrogel patterning and flow channels to pattern 
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different cell types for study of angiogenesis and invasion. (ii) Angiogenesis of endothelial 
cells in the middle toward MTLn3 cancer cells and invasion of cancer cells towards the 
vasculature. Adapted from [152] with permission of The Royal Society of Chemistry. (B) (i) 
Microfluidic chip design for creation of microvascular network and angiogenic sprouting. (ii) 
(top) Immunofluorescence staining of a fully functional microvascular network with 
endothelial cells, pericytes, cancer cells, and leukocytes (bottom) Immunofluorescence 
staining of the angiogenic sprouting model. Adapted from [110] with permission of The 
Royal Society of Chemistry. (C) (i) Device schematic of a microdevice holding 3D hydrogel 
with microchannels. (ii) Angiogenic sprouting of endothelium towards different angiogenic 
factors [96].  
Figure 6. Microdevices to model the metastatic niche. (A) A microfluidic vasculature with 
region-specific activation of endothelium for cancer cell adhesion analysis [116]. (B) (i) A 
microfluidic tumor-vascular interface model. (ii) Invasion of the endothelium by 
fibrosarcoma cells [166]. (C) (i) A microfluidic microvascular network platform. (ii) The 
extravasation dynamics of MDA-MB-231 cells. Adapted from [109] with permission of The 
Royal Society of Chemistry. (D) A microdevice to study how the paracrine signaling between 
macrophage, lung adenocarcinoma cells, and myofibroblasts can affect the invasiveness of 
the cancer. Adapted from [177] with permission of The Royal Society of Chemistry. (E) The 
tubeless lumen model to study invasive transition of MCF10aDCIS ductal carcinoma by 
mammary fibroblast [180]. 
Figure 7. Microdevices for tumor-on-a-chip studies. (A) Establishment of Vascularized 
Micro-Organs (VMOs). (i) A schematic depicts the microfluidic platform of the VMO, which 
consists of a thick layer of PDMS with patterned tissue chambers and microfluidic channels, 
bonded on top of thin PDMS membrane and a glass cover slip. The cell-ECM suspension is 
injected through the gel-loading ports at either end of the tissue chamber. The four media 
  34
reservoirs are attached to the inlets and outlets of the microfluidic channels. (ii) A depiction 
of a representative tissue chamber at day 7 with a fully developed vascular network. 
Transduced endothelial cells, shown in red, are migrating out and fusing with microfluidic 
channels. This platform is used later in the study to establish a human colon cancer micro-
tumor. Adapted with permission from Nature Publishing Group. (B) A human breast cancer-
on-a-chip. (i) A depiction of DCIS (carcinoma) in a mammary duct, with basement 
membrane, epithelium, stroma, and capillary blood flow. Adapted from [13] with permission 
from the Royal Society of Chemistry. (ii) An image showing the interaction between breast 
cancer cells and an artificial microvessel embedded in a microfluidic tumor-on-a-chip device. 
Adapted from [98] with permission from the American Association for Cancer Research. (C) 
Design of microfluidic chip for tumor spheroid-fibroblast co-culture. This chip is used for 3D 
co-culture of human colorectal cancer cells and fibroblasts. There are four units per chip and 
7 channels per unit for loading with either cells or media. The bottom-left shows in detail a 
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